[1] Kassure EG.Drug-reactions complications in infants and children[J].Am J Roentgen,1991,1(1):4-7. [2] Li LJ,Hu JH,Wang Z,et al.Establishment of a new standard for evaluation of grade of adverse drug reaction severity and application of adverse drug reaction severity index[J].Pharmaceutical Care and Research(药学服务与研究),2008,8(1):9-13. [3] Pharmacopoeia committee of ministry of health of people's republic of China.Chinese pharmacopoeia part I (中国药典一部)[S].Beijing:China Medical Science and Technology Press,2020:1097-1098. [4] Expert committee on rational drug use,Ministry of health.guidelines for clinical drug use of Chinese pharmacists ( 中国医师临床用药指南)[M].2nd ed.Chongqing:Chongqing publishing house,2014:1-1674. [5] Chen DY,Chen WB.Clinical pharmacotherapy[M].4th ed.Beijing:People's Medical Publishing house (临床药物治疗学),2012:l-710. [6] Zhao X,Lin P,Guo J,et al.Pareto chart analysis of irrational drug use in outpatient and emergency of our hospital[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2018,15(7):429-433. [7] Trab C,Knowles SR,Liu BA,et al.Gender differences in adverse drug reaction[J].Clin Pharmacol,1998,38(11):1003-1009. [8] Wang SF,Sun DR,Wang GL,et al.Adverse drug reactions (药物不良反应)[M].Beijing:People's Medical Publishing House,1988:17. [9] Wang XY.Analysis of adverse drug reactions in 94 neonates in children's hospital[J].Pharmaceutical Research(药学研究),2019,38(10):615-620. [10] Chen YW,Li ZP.Pharmacokinetics of antifungal agents in newborns and infants[J].Chinese Journal of New Drugs and Clinical Sciences,2014,33(2):90-96. [11] Sherwin MT,Medlicott NJ,Reith DM,et al.Intravenous drug delivery in neonates:lessons lear[J].Archives of Disease in Childhood,2014,99(6):590-594. [12] Li YX,Li SJ,Zhang Y,et al.Progress in the application and pharmacokinetic characteristics of tacrolimus in living donor liver transplantation in children[J].Tianjin Pharmacy(天津药学),2017,29(4):54-57. [13] Wang F,Li YH,Guo RF,et al.Literature analysis of 376 cases of adverse drug reactions induced by ceftriaxone sodium for injection[J].Journal of Pharmacovigilance(中国药物警戒),2019,16(5):289-295. [14] Miline CP,Bruss JB.The economics of pediatric formulation development for off-patent drugs[J].Clin Ther,2008,30(11):2133-2145. [15] Zhang J.Pharmacokinetic characteristics of levetiracetam oral administration in neonates[J].Chinese Journal of Clinical Rational Drug Use(临床合理用药杂志),2016,9(19):112-113. [16] Wu MZ.A population pharmacokinetic study of caffeine prevention and treatment of apnea in premature infants[D].Guangzhou:Guangzhou Medical University(广州医科大学),2017:4-7. [17] Hu X,Liu X,Lang LJ,et al.The composition and rationality evaluation of drug use for pediatric emergency respiratory diseases in our hospital[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2018,15(12):741-745. [18] Wang XL,Zhang TH.Challenges and strategies in pediatric pharmacokinetic study[J].Journal of International Pharmaceutical Research(国际药学研究杂志),2016,43(4):621-631. [19] Xiao Y,Wan JJ,Lai CH.Investigation and analysis on the information of the children in the 1132 drug instruction[J].China Modern Medicine(中国当代医药),2016,23(18):72-74. |